Skip to main content
Clinical Trials/EUCTR2012-002573-62-SE
EUCTR2012-002573-62-SE
Active, not recruiting
Phase 1

Doppler quantitative evaluation and follow-up over 12 months in RA patients with moderate and high disease activity who are candidates for biologic add-on therapy with Adalimumab

The Karolinska Institute, ClinTRID0 sites120 target enrollmentAugust 14, 2012

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Rheumatoid arthritis (RA)
Sponsor
The Karolinska Institute, ClinTRID
Enrollment
120
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 14, 2012
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
The Karolinska Institute, ClinTRID

Eligibility Criteria

Inclusion Criteria

  • Adult patient (\> 18 years of age), male or female
  • Rheumatoid arthritis according to the 1987 ACR or 2010 EULAR/ACR classification criteria
  • Moderate to high disease activity
  • Ongoing anti\-rheumatic treatment with DMARD, with stable dosage during the last 3 months, and being a candidate for anti\-TNF add\-on therapy OR ongoing treatment with first anti\-TNF therapy and being a candidate for switch to another anti\-TNF therapy
  • Women with child\-bearing potential: use of an adequate method of contraception to avoid pregnancy throughout the study
  • Signed Informed Consent\*
  • \* Signed Informed Consent must be obtained before any study specific procedures take place.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes

Exclusion Criteria

  • Biologic treatment with Adalimumab before inclusion
  • Two or more ongoing biologic treatments before inclusion
  • Treatment with other biologic treatment than anti\-TNF therapy before inclusion
  • Any contraindication for treatment with Adalimumab
  • Intraarticular corticosteroid injection during the last 4 weeks before each follow\-up visit
  • Positive for tuberculosis or hepatitis B.
  • Ongoing pregnancy or lactation

Outcomes

Primary Outcomes

Not specified

Similar Trials